Ruth Calder

Ruth Calder covers enforcement for GLP Watchdog: FDA warning letters and untitled letters, state pharmacy-board licensing and disciplinary actions, 503A and 503B registration status, and the corporate-entity records that connect brands to the operators behind them.

Her work starts from primary documents. Every enforcement claim on this site is matched to a specific letter, registration record, or filing by company name and address, never by a name that merely looks similar. The recipient is identified from the document itself, not from how a seller or a competitor describes it. Where a claim rests on an absence (a seller is not registered, or no action has been taken), that absence is confirmed against a positive control, a search known to find a real record, because a search that returns nothing is as often a broken search as a clean record.

This work is held to the beat, the method, and the sourcing standard above. GLP Watchdog makes no claim that Ruth Calder holds a clinical license, an academic post, a pharmaceutical-industry role, a patent, or any other professional credential. There are none behind this byline, and none is implied. The byline stands behind the documents cited in each piece, which a reader can pull independently.

Nothing here is medical advice. Where a piece states something clinical, the statement traces back to an FDA-approved label, a primary study indexed in PubMed, or a regulatory filing identified by name. The piece says which of the three it is, so a reader can weigh the source instead of taking it on trust.

GLP Watchdog is reader-supported through affiliate commissions on some provider links. Ruth's enforcement coverage is produced without regard to which sellers are commercial partners, and this site has flagged a partner. Where a piece concerns a company we earn from, the page itself discloses that relationship, on the row it applies to. The full policy is at /disclosure; the scoring methodology is at /methodology.